Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-03-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2022年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2022 by Yunnan Watson Biotechnology Co., Ltd. It includes financial figures such as beginning and ending balances, interest amounts, and repayment amounts. The document is relatively short (1985 characters) and focuses on specific financial data related to related party transactions rather than a comprehensive financial report. It does not appear to be an annual report, interim report, or earnings release. It is not an announcement or a certification but a financial summary related to related party transactions. Such detailed financial data about related party transactions typically falls under Regulatory Filings (RNS) as it is a compliance disclosure and does not fit other specific categories like Annual Report or Interim Report. Therefore, the best classification is Regulatory Filings (RNS).
2023-03-29 Chinese
关于公司董事长及其控制的企业增持公司股份计划实施进展暨增持时间过半的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a share increase plan by the company's chairman and related entities. It details the number of shares acquired, the amount spent, the timeline of the plan, and the current shareholding percentages before and after the increase. The document does not contain financial statements or detailed financial performance data. It is a regulatory disclosure about insider share transactions, specifically the chairman's and his controlled entities' purchase of company shares. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is 2520 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the correct classification is DIRS (Director's Dealing).
2023-03-21 Chinese
关于变更公司发行股份购买资产并募集配套资金项目独立财务顾问主办人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the independent financial advisor for a company's project involving issuance of shares to purchase assets and raising supporting funds. It details the replacement of the advisor due to work changes and provides a brief resume of the new advisor. There is no financial data, report, or detailed analysis presented. The document is a regulatory announcement about a change in advisory roles related to financing activities, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and focused on a specific financing advisory change, confirming the classification.
2023-03-17 Chinese
关于自愿披露新型冠状病毒变异株mRNA疫苗Ⅲb期临床试验主要结果的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the main results of a Phase IIIb clinical trial for a COVID-19 mRNA vaccine. It contains detailed clinical trial data on safety, immunogenicity, and efficacy, but it is not a financial report or regulatory filing related to financial performance. The document is an announcement of clinical trial results, which is a regulatory disclosure but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The best fitting category is Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial results that does not fit other specific categories.
2023-03-17 Chinese
关于全资子公司完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration changes for wholly-owned subsidiaries, including capital increase and changes in registered addresses and appointment of directors/supervisors. It contains no financial statements, no earnings data, no meeting materials, no voting results, no legal proceedings, and no mention of report publication. The document is an official announcement about corporate structural changes and administrative updates related to subsidiaries. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like MANG (management changes) because it focuses on subsidiary registration and capital increase details rather than direct board or senior management changes at the parent company level.
2023-03-14 Chinese
关于公司董事长及其控制的企业增持公司股份计划实施进展的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a shareholding increase plan by the company's chairman and entities controlled by him. It details the number of shares acquired, the amount spent, and the purpose of the share increase. It includes specific shareholding percentages before and after the increase and discusses the risks related to the implementation of the plan. This type of document is a report on transactions in the company's own shares by directors and related parties, which fits the definition of Director's Dealing (DIRS). The document is not a full financial report, earnings release, or regulatory filing, but a specific disclosure about insider share transactions.
2023-03-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.